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 Muscular atrophy, defined as the loss of muscle tissue, is a serious issue for 
immobilized patients on Earth and in human spaceflight, where microgravity prevents 
normal muscle loading. In vitro modeling is an important step in understanding atrophy 
mechanisms and testing countermeasures before animal trials. The most ideal 
environment for modeling must be empirically determined to best mimic known 
responses in vivo. 
 To simulate microgravity conditions, murine C2C12 myoblasts were cultured in a 
rotary cell culture system (RCCS). Alginate encapsulation was compared against 
polystyrene microcarrier beads as a substrate for culturing these adherent muscle cells. 
Changes after culture under simulated microgravity were characterized by assessing 
mRNA expression of MuRF1, MAFbx, Caspase 3, Akt2, mTOR, Ankrd1, and Foxo3. 
Protein concentration of myosin heavy chain 4 (Myh4) was used as a differentiation 




 Differentiated C2C12 cells encapsulated in alginate had a significant increase in 
only MuRF1 following simulated microgravity culture and were morphologically 
dissimilar to normal cultured muscle tissue. On the other hand, C2C12 cells cultured on 
polystyrene microcarriers had significantly increased expression of MuRF1, Caspase 3, 
and Foxo3 and easily identifiable multi-nucleated myotubes. The extent of differentiation 
was higher in simulated microgravity and protein synthesis more active with increased 
Myh4, Akt2, and mTOR. The in vitro microcarrier model described herein significantly 
increases expression of several of the same atrophy markers as in vivo models. However, 
unlike animal models, MAFbx and Ankrd1 were not significantly increased and the fold 
change in MuRF1 and Foxo3 was lower than expected.  
Using a standard commercially available RCCS, the substrates and culture 
methods described only partially model changes in mRNAs associated with atrophy in 
vivo. Nevertheless, our results in vitro are highly significant for MuRF1 (p<0.01), Foxo3 
(p<0.01), and Caspase 3 (p<0.001), indicating that with further development, simulated 
microgravity systems may present a promising system for investigation of atrophy 
pathways and first-step design and selection of novel therapeutics necessary to ensure 
















In Vitro Simulation of Microgravity Induced Muscle Loss Successfully Increases 
Expression of Key In Vivo Atrophy Markers 
Charles P. Harding 
 
Muscle loss from lack of activity is a serious issue for immobilized patients on 
Earth and in human spaceflight, where the low gravity environment prevents normal 
muscle activity. Simulating muscle loss in cultured cells is an important step in 
understanding how this condition occurs. This work evaluates different means of 
simulating muscle loss and selects the one that most closely mimics the cellular responses 
seen in animals and humans. 
 To simulate the microgravity environment of spaceflight, mouse skeletal muscle 
cells were grown in a rotary cell culture system (RCCS). Growing the cells within a 
natural gelled substrate was compared against growing them on the surface of small 
plastic beads. Changes after culture under simulated microgravity were characterized by 
assessing proteins and genes known to change during muscle loss. The structure of the 
cells was also evaluated by microscopy. 
 The mouse skeletal muscle cells grown on plastic beads in the RCCS had 
significant changes in multiple key genes associated with muscle loss and demonstrated 
physical characteristics expected of mature tissue in live animals. This model is a 
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Motivation and Scope 
 
 Skeletal muscle loses significant strength and mass during extended periods of 
inactivity, with losses of 40% reported after 6 months in orbit[1]. Not limited to 
spaceflight, the causes of inactivity also include immobilization of broken limbs, 
paralysis, and bed rest. Reducing muscle loss associated with inactivity is critical for 
preserving the strength and endurance of astronauts, especially with future long-term 
missions planned for Mars. Muscle mass loss for short duration missions ranges from 10-
20%, compared to 30-50% for long duration missions[2, 3]. To reduce these risks, flight 
protocol at the National Aeronautics and Space Administration (NASA) mandates that 
crew members exercise on missions lasting over 10 days; however, loss of strength and 
muscle mass has been reported after only 5 days[4, 5]. Earth-bound patients would also 
benefit from faster recovery times and reduced need for physical therapy following 
serious injuries. Approximately 40-50% of total body mass is skeletal muscle and its loss 
can induce numerous detrimental physiological changes, including reduced power, lower 
endurance, and atypical reflex responses[6, 7]. While many promising anti-atrophy 
compounds have been identified, testing them in actual spaceflight conditions would be 
prohibitively expensive and time consuming.  
 Modeling the atrophy-inducing microgravity environment of space in a ground-
based laboratory has several challenges. The multiple animal models of atrophy, 




affect a small portion of the body. While localized atrophy effects can be studied using 
these methods, systemic effects of whole body atrophy, as would be experienced in 
spaceflight, are not accurately modeled. Localized, tissue-specific atrophy can also be 
modeled in vitro at a significantly lower cost and without the regulatory oversight 
necessary for animal models. Clinostats and rotary cell culture systems move the cells 
such that the sum of gravitational vectors over time is approximately zero. However, the 
growth substrate and culture process must be optimized for the selected cell line to 
maximize changes in the desired atrophy markers versus the control. 
Here, we have developed a ground-based model that mimics microgravity-
induced expression of the mRNA atrophy markers MuRF1, MAFbx, and Caspase 3 in 
vitro using a rotary cell culture system and the C2C12 mouse skeletal muscle cell line. 
This model provides consistent and significant increases in the selected markers and a 
means of screening anti-atrophy therapeutics prior to testing in vivo. Additionally, 
external radiation can be applied to the system to more accurately mimic the spaceflight 
environment. We expect the model will be valuable for probing atrophy mechanisms and 
expediting the search for pharmaceuticals that enable long-duration spaceflight missions 




 This thesis describes development of a model for mimicking atrophy of skeletal 
muscle cells in vitro, including growth substrate selection, application of low-dose 




and mRNAs. Chapter 2 provides a background on the mechanisms of spaceflight atrophy 
and a literature review of atrophy modeling in vivo and in vitro. Additionally, it 
highlights where the model developed herein fits into the current body of literature. 
 Chapter 3 details the preliminary work in developing the microgravity model. 
Selection of an appropriate control vessel, growth substrate, and culture methodology is 
discussed. Use of amino acid and metabolite analysis for distinguishing between normal 
gravity controls and simulated microgravity conditions is evaluated. Finally, addition of 
low-dose gamma radiation is investigated.  
Chapter 4 is a manuscript prepared for the Utah NASA Space Grant Consortium. 
Chapter 5 contains the final model and metrics developed in this thesis, as will be 
submitted for publication. Chapter 6 summarizes the main findings of this thesis and 
concludes with future work involving anti-atrophy compounds, higher-dose radiation, 














CHAPTER 2  
BACKGROUND AND LITERATURE REVIEW 
Mechanisms of spaceflight atrophy 
 
 Astronauts experience significant muscle loss in spaceflight despite the current 
International Space Station exercise program[8]. Disuse, reduced protein synthesis, and 
reduced motor neuron activity all contribute to loss of muscle tissue and strength in 
spaceflight[6]. The degree of atrophy is dependent on anatomical region and duration of 
exposure to the microgravity environment. Short duration missions can result in a 10-
20% loss of muscle mass, where losses in long duration missions can range from 30-
50%[2, 3]. Atrophy is more severe for muscles responsible for maintaining posture under 
normal gravity, with the intrinsic back muscles losing 10.3% volume compared to 3.9% 
for calf muscles after 8 days of spaceflight[2, 9]. Atrophy affects cardiac muscle in 
addition to skeletal muscle, with a decrease in left ventricular mass of 12% following 10 
days of spaceflight[10]. Preventing muscle atrophy would preserve the strength and 
endurance of astronauts and help enable longer duration space travel and exploration. 
The mRNA atrophy markers MuRF1, MAFbx, and Caspase 3 are all critical 
components of muscle tissue breakdown via the ubiquitin proteasome pathway. In this 
pathway, ubiquitin—a polypeptide co-factor—attaches to the protein to be degraded, the 
complex is recognized by the 26S proteasome, then broken down into its constituent 
amino acids[11]. There are three enzymes involved in attaching ubiquitin to the protein, 
E1, E2, and E3. The E3 ubiquitin ligases are the most diverse group, with up to 1000 




in attaching ubiquitin to proteins are MuRF1 and MAFbx, both upregulated in a wide 
range of atrophy models including denervation, hindlimb unloading, immobilization, bed 
rest, multiple diseases, spaceflight, and aging[12, 13]. MAFbx and MuRF1 aren’t 
upregulated for all types of atrophy. Contrary to atrophy from immobilization, 
sarcopenia, or age-related muscle loss, results in a down-regulation of these key ubiquitin 
ligases, indicating that multiple mechanisms need to be investigated for a total picture of 
muscle loss[14]. This thesis focuses on loss from a simulated microgravity environment. 
The role of the third mRNA marker, Caspase 3, comes into play in the first stages 
of atrophy. Intact muscle fibers can’t be degraded by the ubiquitin proteasome system 
and must be broken down before MuRF1 and MAFbx can act. Reactive oxygen species—
increased during muscular atrophy—upregulate calpains, which degrade multiple muscle-
related proteins, including titin, nebulin, actin, and myosin[7]. Reactive oxygen species 
(ROS) also increase Caspase 3, which breaks down actomyosin complexes in the muscle 
tissue[7, 11]. Treatment with vitamin-E, a potent antioxidant, significantly reduced 
Caspase 3 expression in mice subject to 14 days unloading, but did not bring the 
expression level all the way down to the control[15]. A cell culture model that 
successfully mimics in vivo atrophy should demonstrate upregulation of Caspase 3 for the 
initial stages of muscle breakdown, as well as MuRF1 and MAFbx for the later stages of 
protein recycling via the ubiquitin proteasome system.  
Blocking the ubiquitin proteasome system can have therapeutic effects, but is not 
a feasible method for attenuating atrophy. Antigenic peptides produced following protein 
degradation are presented to lymphocytes, which then produce antibodies[11]. One such 




an immunosuppressant[16]. Likewise, blocking Caspase 3 to prevent muscle atrophy is 
not a viable solution. Caspase 3 inhibited C2C12 cells and primary myoblasts from 
Caspase 3 null mice displayed markedly reduced differentiation[17].  
 In addition to upregulating Caspase 3, ROS play an additional role in muscle 
atrophy via degradation of muscle fibers[18]. As astronauts travel past the protection of 
the Earth’s magnetic field, they experience increased radiation levels which generate 
ROS by the radiolysis of water[19]. Even after returning to Earth, ROS generated by 
microgravity and irradiation can continue to disrupt cellular systems. Harmful radiation 
in space primarily comes in two forms, gamma rays and high energy heavy ions[20]. 
Radiation intensity fluctuates depending on solar activity and proximity to the Earth. The 
lowest radiation dose rates occur when in close proximity to the Earth and during the 
solar maximum[20]. Gamma rays are a form of electromagnetic radiation with no mass 
while high energy heavy ions are atomic nuclei stripped of electrons and moving at 
relativistic velocities. Some high energy heavy ions are produced by the Sun, but most 
come from distant supernovae.  
Relative biological effectiveness (RBE) is a measure of how damaging a 
particular type of radiation is to living tissue. Gamma radiation is assigned an RBE of 1 
by definition. High energy heavy ions can have RBE values ranging from 20-40, 
indicating significantly more tissue damage for an equivalent dose[21]. Although high 
energy heavy ions present a greater health hazard in spaceflight, they are difficult to 
simulate in a laboratory and require large particle accelerators to produce.  In contrast, 




regarding epidemiological studies in radiation-exposed humans, rodents, and non-human 
primates. 
NASA limits astronaut radiation exposure to levels that correspond with a 3% 
increase in fatal cancer risk[22]. Long-term missions beyond low Earth orbit, such as a 
journey to Mars, exceed this limit within a single mission and increase the risk of 
developing cancer[20]. Due to the highly penetrating nature of high energy ions in 
cosmic radiation, shielding the spacecraft is not economically feasible[20]. Biological 
countermeasures to radiation damage and increased cancer risk provide an attractive 
alternative to heavy and costly shielding. 
One cellular response that counters radiation damage is the up-regulation of heme 
oxygenase-1 (HO-1)[23, 24]. HO-1 is induced in response to oxidative stress and 
combats this stress in part by degrading heme into biliverdin-IXα, a natural antioxidant 
and anti-inflammatory[25]. Artificial induction of HO-1 has demonstrated protective 
effects against ionizing radiation in multiple tissue types[24, 26]. Another promising 
atrophy and radiation countermeasure is vitamin E. The antioxidant effects of vitamin E 
scavenge free radicals and reduce expression of calpains and Caspase 3, -9, and -12, 
reducing muscular atrophy due to immobilization and unloading[27, 28]. In addition to 
preventing muscle loss, vitamin E also preserves bone mass and strength following 
unloading[29]. Several forms of vitamin E have  demonstrated radioprotective effects, 
including α-tocopherol, δ-tocotrienol, and γ-tocotrienol[30–32]. 
 In summary, muscular atrophy is a complex process involving multiple pathways 
interlinked with other critical cellular functions. Understanding how modifying one 




modeling, as described in this thesis, is well suited to evaluating changes in cell 
metabolism and mRNA expression induced by experimental drugs. 
 
Atrophy modeling in vivo 
 
A classic method for simulating weightlessness is the hind limb unloading rodent 
model, developed at NASA in the 1970’s[33]. In this model, the rodent is affixed in a 
harness or tail traction device such that the hind limbs are elevated at a 30° angle[33]. 
The resulting unloading induces differential muscle atrophy in the hind limbs and 
cephalic fluid shift similar to real microgravity conditions[33]. Three commonly 
measured mRNAs in muscle loss modeling are muscle RING finger-1 (MuRF1), muscle 
atrophy F-box (MAFbx), and Caspase 3, all upregulated in numerous rodent models of 
muscular atrophy including disease, immobilization, hind limb unloading, as well as 
spaceflight[12, 15, 34–45]. Following hind limb unloading, knockout mice lacking 
MuRF1 and MAFbx display significantly less atrophy than wild type mice, highlighting 
the importance of those ligases in the mechanisms underlying muscle loss[12, 35].  
Cages for hindlimb unloading must be designed to accommodate the specific 
requirements of each experiment. Metabolism can be monitored by attaching a specially 
designed urine and feces separator to the bottom of the cage[46]. If radiation will also be 
administered, the animal must either be moved to a smaller container that restricts 
movement, thereby ensuring the dose is consistent and localized, or a lower dose 
radiation source must be attached to the cage itself[47, 48]. A lower activity radiation 




duration of the experiment. This constant, lower level dose is more similar to spaceflight 
than periodic acute doses. However, if additional types of radiation, such a proton or 
heavy ion, are desired, the animals must be moved to a synchrotron or particle accelerator 
and an acute dose administered. 
Animal models have the benefit of providing a variety of tissue types following 
completion of microgravity simulation and irradiation. In addition to muscle tissue, 
hindlimb unloading and irradiation studies have investigated bone, cardiovascular 
function, immunology, renal function, neurology, reproductive systems, and oxidative 
stress[49–53]. 
In conclusion, animal models using hindlimb unloading and other immobilization 
methods are a common and effective means of simulating multiple changes, including 
atrophy from the microgravity environment. However, ground-based animal models are 
more time consuming, more expensive, and are subject to more regulation than cell 
culture models, providing strong motivation to develop other methods. Newly developed 
therapeutics can be effectively screened with smaller quantities in cell culture models and 
safe dose ranges established prior to testing in vivo. 
 
Atrophy modeling in vitro 
 
 In vitro simulation of microgravity can be conducted with rotary culture systems 
and 3D random positioning machines or clinostats[54, 55]. In vitro microgravity 
simulation has the benefits of lower costs and fewer regulatory concerns compared to 




elicit a response is lower for small in vitro systems, conserving therapeutics that may be 
difficult to produce at early stages of development. 
 
 
Figure 1. Microcarrier clusters with C2C12 cells suspended in the RCCS. 
 
 Atrophic conditions can be generated in ground-based laboratories with a rotary 
cell culture system (RCCS), developed by Synthecon Inc. in conjunction with NASA to 
simulate microgravity[54]. Microgravity is simulated by the rotational motion of the 
vessel maintaining cells at their terminal settling velocity, similar to what astronauts 
experience in orbit around Earth [Figure 1]. Fluid flow in the RCCS had been designed to 





, where 𝜌𝑎  is the density of the cell aggregate, 𝜌 is the density of the 




When the substrates are maintained at their terminal settling velocity, the force of gravity 
𝐹𝑔 is described by Stoke’s Law. 




The resulting 𝐹𝑔 is balanced by the drag force from the rotating fluid, resulting in a net 
force of zero. Since 𝑔 and 𝑅 are constant at any given moment, the ratio of 𝐹𝑔  in the 
RCCS to the normal force of gravity can be simplified to express how many times normal 























As a result, the final force of gravity on the cells is dependent entirely on the density of 
the substrate and surrounding fluid. To minimize the force of gravity, a cell culture 
substrate with a density close to that of water should be selected.  
The RCCS has been used to simulate microgravity in a variety of cell types, 
including lymphocytes, osteoblasts, and myoblasts[57–59]. The C2C12 cell line used in 
the experiment presented herein is a mouse myoblast line that can differentiate into 
contractile skeletal muscle fibers. The cells can be tested in their undifferentiated state to 
investigate effects on developing tissue, as well as in their differentiated state to 
investigate effects on mature tissue. First cultured in 1977, the C2C12 cell line produces 
many of the same proteins and mRNAs as human muscle tissue, making it a suitable 
analog for investigation of atrophic conditions[60]. 
As an adherent cell line, C2C12 cells require a substrate for growth. A three-
dimensional scaffold suitable for culture of adherent cell lines such as C2C12’s can be 




of a scaffold should include considerations for compatibility with the desired cell type, 
physical characteristics, diffusion rate, and ease of gelling and dissolution. Scaffolds such 
as poly(lactide-co-glycolide) (PLG) have good mechanical properties and excellent 
biocompatibility for use in vivo, but harsh processing conditions makes encapsulation of 
viable cells challenging[61]. Other synthetic polymers such as poly(ethylene oxide) 
(PEO) and  poly(vinyl alcohol) (PVA) have established medical applications for tissue 
engineering and drug delivery, but photo-crosslinking of PEO with UV light and PVA 
with repeated freeze-thaw cycles or glutaraldehyde would damage encapsulated cells[61]. 
In contrast, the naturally occurring hydrogel alginate has well established uses for cell 
encapsulation due to low toxicity and gentle gelling conditions[61–66]. The high porosity 
of alginate hydrogels is advantageous for maximizing diffusion rates and ensuring 
adequate exchange of nutrients and waste products with the surrounding culture 
media[62]. Dissolution of alginate hydrogels for cell harvesting can be accomplished 
with a neutral buffered solution of sodium citrate. 
Encapsulation of mammalian cells in alginate hydrogels to generate 3D cultures 
has been performed on many cell types, including stromal vascular cells, Leydig cells, 
baby hamster kidney cells, epithelial cells, fibroblasts, and myoblasts[63–66]. Diffusion 
of nutrients through the alginate bead is a function of molecule size and the percentage of 
alginate, with smaller molecules and lower alginate percentages resulting in faster 
diffusion[67]. The percentage alginate used for encapsulation can be varied between 1.5-
3% (w/v) depending on the cell type and desired mechanical properties[63–66, 68]. To 
preserve bead integrity in the dynamic RCCS environment, we elected to encapsulate 




2][62]. Mechanical stability of alginate beads can also be modified by complexing with 
chitosan[63]. Additionally, alginate beads can be formed in various sizes by changing the 
gauge of the needle used for extrusion. In contrast with microcarrier beads, which are 
limited to seeding with undifferentiated cells, alginate encapsulation can be performed on 
both undifferentiated and differentiated muscle cells. The tunable properties and low cost 
of alginate hydrogels make them an attractive substrate for 3D cultures. 
 
 
Figure 2. C2C12 cells suspended in 3% w/v alginate solidifying in 200 mM CaCl2, 
10mM HEPES 
 
 Another option for culturing adherent cells in the suspension environment of the 
RCCS is microcarriers, small synthetic beads with a suitable surface chemistry [Figure 
3]. The ease of scalability makes microcarriers an attractive substrate for producing large 




chemistries are available from suppliers to tailor the beads for specific cell types and 
culture conditions[69]. Successful culture of muscle cells on microcarriers has been 
reported with dextran, collagen, and polystyrene surfaces[56, 71, 72]. While a more 
expensive substrate than alginate, the variety of commercially available bead types, ease 
of use and facile scalability make microcarriers an industry standard for suspension 
culture of adherent cells. 
 
 




Previously published work with muscle cells, including C2C12s, in simulated 




59, 73]. To the best of the authors’ knowledge, no previously published work has 
investigated changes in atrophy-specific mRNAs with muscle cell culture in the RCCS. 
The work presented in this thesis combines the mRNA analytics of in vivo atrophy 
modeling with the in vitro RCCS, supporting use of cultured muscle cells in 


























 This section covers selection of the control cell culture vessels and alginate 
encapsulation conditions used in Chapters 4 and 5. Additionally, metrics for 
distinguishing between control and simulated microgravity conditions are discussed. We 
initially sought to use analysis of cell metabolites and amino acids to determine culture 
status. However, these methods did not have sufficient resolution to distinguish between 
conditions. Nevertheless, key results of branch chain amino acid levels and glucose 
consumption are presented to demonstrate typical concentrations under simulated 
microgravity conditions. 
 
Selection of static control vessel for microcarriers 
 
 A control vessel in a simulated microgravity cell culture model should meet three 
criteria: same volume as RCCS vessels, suitable surface chemistry, and single 
gravitational vector. An identical media volume is needed to control for the quantity of 
nutrients available to the cells. A low adhesion surface chemistry in the control vessel is 
critical in microcarrier cultures to force cells to grow only on the microcarrier beads. Use 
of a cell culture treated flask with microcarriers provides a larger surface area for growth 
than would be available in the RCCS and results in microcarriers stuck to the surface of 




results in a single primary gravitational vector, such as an orbital shaker at low speed or 
rocker plate. 
Two vessel types were evaluated for culture of microcarriers as a normal-gravity 
control, the Nunc OptiCell cartridge and the Corning ultra-low attachment flask [Figure 
4]. Both vessels have a 10 mL working volume, equivalent to that of the vessels used 
with the RCCS. The OptiCell cartridge has the advantage of a gas-permeable membrane 
with a high surface area to volume ratio, resulting in increased oxygen saturation during 
the earlier stages of the culture [Figure 5]. However, the cartridge requires all fluid 
handling be done through a syringe needle, which is easily clogged by the microcarrier 
beads. Due to the clogging, added expense of using syringes instead of pipette tips, and 
dissimilar dissolved oxygen profile compares to the RCCS, T25 flasks with an ultra-low 
attachment surface were selected as the normal gravity control vessels. 
Initially, the control flasks were cultured on a rocker plate to account for fluid 
motion in the RCCS. However, the rocker plate forced all the microcarrier beads into a 
single large mass not representative of the cluster sizes in the RCCS. A low speed orbital 
shaker produced a similar result. When properly filled and absent of air bubbles, shear 
forces from fluid motion in the RCCS are negligible and selecting a control with similar 
bead cluster morphology is preferred[54]. Therefore, static ultra-low attachment flasks 

































Optimization of encapsulation conditions 
 
 Encapsulating and immobilizing cells within an alginate hydrogel is another 
means of generating a 3D cell mass. Unlike microcarriers, where monolayers of cells 
freely grow on the surface of the substrate, alginate encapsulation locks cells in place 
within the substrate. The conditions under which cells are encapsulated, including cell 
density, alginate percentage, and the use of additives such as chitosan can all influence 
the culture performance. This section discusses the steps taken to determine the 
encapsulation parameters best suited for use with the RCCS. 
The cell density for encapsulation was selected to maximize cell-cell contact 
within the alginate bead while maintaining bead integrity. It was observed that cells have 
difficulty spreading through the bead, likely due to the high density of the 3% w/v 
alginate substrate. While the percentage alginate used for encapsulation can be varied 
between 1.5-3% (w/v), we elected to encapsulate cells at the upper end of this range to 
maximize mechanical strength of the beads in the dynamic RCSC environment[62–66, 
68]. 
To limit the distance the cells needed to spread before contacting another cell, 
seeding density optimization was performed. Undifferentiated cells were encapsulated at 
densities of 0.25, 0.5, 1, and 10x106 cells/mL alginate. Differentiated cells were 
encapsulated following 10 days of culture in standard tissue culture flasks, after which 
there were removed with a cell scraper and encapsulated at 75 or 150 cm2 of flask area 




 A syringe pump with a multi-syringe head was used to form alginate beads at 
multiple encapsulation densities simultaneously [Figure 6]. With a 19 gauge needle and a 
flow rate of 2 mL/min, the average bead size was 3251±103 µm, n=10. The size of the 
beads formed with this method is too large to be aspirated with a serological pipette, 
requiring the beads to be poured into their culture containers. Use of smaller needles was 




Figure 6. Syringe pump setup for formation of multiple cell-alginate ratio beads. 
 
 With undifferentiated cells, the appearance of the beads under brightfield imaging 




concentration of 10x106 cells/mL, bead shape was highly spherical. The highest cell 
density also affords the greatest chance of cell-cell contact necessary for differentiation 
into multi-nucleated myotubes. 
With differentiated cells, at a density of 75 cm2/mL the beads were mostly full of 
tissue and still maintained circularity [Figure 8]. At a higher density of 150 cm2/mL, the 
beads did not harden into spherical shapes and some droplets broke apart on contact with 
the CaCl2 solidification buffer [Figure 9]. Therefore, 75 cm
2 of flask area per milliliter of 
alginate was selected as the ratio for encapsulation of differentiated cells. 
 The standard alginate croslinking process solidifies the hydrogel, but the beads 
remain fragile and may be damaged by mechanical forces in the RCCS. Use of chitosan 
to coat the beads was investigated as a means of improving mechanical durability. 
Confluent and differentiated C2C12 cells were scraped and encapsulated in alginate 
beads at a density of 75cm2/mL alginate. Alginate beads were solidified both with and 
without cells in either a 0.2 M CaCl2 solution or a 0.5% chitosan solution with 13 mM 
HEPES and 1.5% (0.135 M) CaCl2[63]. 30 alginate beads were created for each 
condition. The media was DMEM 10% FBS and was not changed over the duration of 
the experiment. After 15 days, the beads were removed from the RCCS vessels and 
imaged. The –Cells +Chitosan vessel had 28/30 beads still present. All other conditions 
had all 30 beads intact. Significant debris was observed in the +Cells +Chitosan condition 
[Figure 10 B]. The debris was not present in the +Cells –Chitosan condition [Figure 10 
A]. No significant difference was observed in the condition of the beads themselves, but 
the presence of debris and loss of two beads suggests that 0.5% chitosan may negatively 





Figure 7. Encapsulation of undifferentiated C2C12 cells at 0.25 (A), 0.5 (B), 1 (C), and 








Figure 8. Differentiated cells encapsulated at 75 cm2/mL alginate 
 
 






Figure 10. Encapsulated differentiated cells after 15 days of culture in beads without (A) 
and with (B) chitosan. 
 
Amino acid and glucose analysis 
 
Amino acid concentrations in cell culture media can provide insight into cell 
metabolism and pathways affected by the experimental conditions. The cell culture 
process requires a media exchange every 3 days, so data on nutrient consumption is 
limited to that same timeframe. Preliminary investigation of amino acid levels was 
performed on day 9 to allow sufficient time for differentiation. A Waters Alliance 2695 
high performance liquid chromatography (HPLC) system was used to analyze alanine 
and the branch chain amino acids (BCAAs) leucine, isoleucine, and valine. Alanine, not 
present in DMEM, is secreted into the bloodstream by muscle fibers while BCAAs are 
oxidized for nutrients[74, 75]. Lower alanine production and BCAA consumption would 




Alanine was produced by the cells in both experimental conditions, but less was 
produced in the simulated microgravity condition [Figure 11]. After 9 days, BCAA 
concentrations were lower in the normal gravity control, indicating higher cell 
metabolism compared to the simulated microgravity condition. [Figure 11]. Due to small 
differences between the simulated microgravity condition and DMEM, as well as the 
regular changing of media introducing variability to the system, HPLC was not used in 
the following chapters. Instead, qRT-PCR was selected to maximize sensitivity and focus 
on atrophy markers supported by a large body of literature. 
 Metabolic activity of the cells was also investigated by measuring glucose 
consumption with a Nova Biomedical BioProfile FLEX. A decrease in consumption 
would indicate attenuated metabolism. Glucose consumption decreased sharply between 
days 6 and 9 for alginate encapsulated cells, while increasing for cells cultured on 
microcarriers [Figure 12]. Conversely, glucose consumption increased during this period 
for the microcarrier condition, indicating a higher metabolic rate and more cell growth. 
The consumption trends are similar for each substrate’s respective normal gravity and 








































Figure 12. Glucose consumption, as measured by the difference between spent media 




 With amino acid results potentially affected by variations in residual media 
volume during periodic media changes and similar glucose consumption profiles between 
RCCS and control conditions, highly sensitive qRT-PCR was selected as the preferred 
metric for use in Chapter 5. For microcarriers, ultra-low attachment flasks were selected 


























Alginate Undifferentiated - Normal Gravity
Alginate Undifferentiated - Simulated Microgravity
Alginate Differentiated - Normal Gravity
Alginate Differentiated - Simulated Microgravity
Microcarriers - Normal Gravity




were not damaged during liquid handling. The optimized encapsulation density of 10x106 
cells/mL and 75 cm2/mL of alginate was used for subsequent work with undifferentiated 
and differentiated cells, respectively. Chitosan was not necessary for the mechanical 
stability of the alginate beads, as 100% of beads without alginate were still intact after the 
15-day culture period. With the culture parameters established in this chapter and qRT-
PCR identified as a necessary metric, subsequent work in Chapter 5 focused on 





















UTAH NASA SPACE GRANT CONSORTIUM PAPER 
In Vitro Modeling of Microgravity-Induced Muscle Atrophy and Spaceflight Radiation 
 
Abstract 
Muscular atrophy, defined as the loss of muscle tissue, is a serious issue for 
immobilized patients on Earth and in human spaceflight, where microgravity prevents 
normal muscle loading. A major factor in muscular atrophy is oxidative stress, which is 
amplified not only by muscle disuse, but also by the increased levels of ionizing radiation 
in spaceflight. Additionally, elevated radiation exposure can damage DNA, increasing 
cancer risk.  
To model oxidative stress and DNA damage generated by conditions on the 
International Space Station, murine C2C12 myoblasts were cultured in a rotary cell 
culture system irradiated by cesium-137. Changes due to the spaceflight model were 
characterized with fluorescent imaging, amino acid analysis, and enzyme linked 
immunosorbent assay for heme oxygenase 1. Fluorescent imaging was performed to 
assess viability, lipid peroxidation, and DNA damage.  
  Minor DNA damage was observed in cells exposed to 20 µCi cesium-137 for 15 
days. No significant differences in viability or lipid peroxidation were noted. Exposure to 
radiation decreased intracellular heme oxygenase 1 and extracellular alanine, but did not 
affect branch chain amino acids. Investigation of stronger radiation sources and extended 
culture time is ongoing. We anticipate that radiation will exacerbate the atrophic effects 




provide a valuable platform for drug discovery and an understanding of the progression 
from normal to disease state.  
Introduction 
Muscular atrophy due to disuse is a serious issue for individuals subject to bed 
rest or prolonged immobilization, as well as in human spaceflight, where microgravity 
prevents normal muscle loading. Atrophy affects cardiac muscle in addition to skeletal 
muscle, with a decrease in left ventricular mass of 8% and 12% following 6 weeks of bed 
rest and 10 days of spaceflight, respectively[10]. Preventing cardiac and skeletal muscle 
atrophy would preserve the strength and endurance of patients subject to extended bed 
rest and immobilized limbs, as well as enable longer duration space travel and 
exploration. 
A major factor in muscular atrophy is increased oxidative stress, where reactive 
oxygen species (ROS) induce degradation of muscle fibers[18]. As astronauts travel past 
the protection of the Earth’s magnetic field, they experience increased radiation levels 
which generate ROS by the radiolysis of water[19]. Even after returning to Earth, ROS 
generated by microgravity and irradiation can continue to disrupt cellular systems. 
Developing countermeasures for atrophy and radiation in spaceflight will require 
extensive screening of promising pharmaceuticals for efficacy, safety, contraindications, 
and dosage schedule. Due to the cost of spaceflight and limited crew time aboard the 
International Space Station, high throughput screening of pharmaceuticals in actual 
microgravity conditions is not economically feasible. We propose a ground-based model, 
detailed herein, to mimic both microgravity and radiation and provide a low cost platform 




patients on Earth, but will also be critical for future spaceflight missions beyond low 
Earth orbit. 
Background 
Atrophic conditions can be generated in ground-based laboratories with a rotary 
cell culture system (RCCS), developed by Synthecon Inc. in conjunction with NASA to 
simulate microgravity[54]. Microgravity is simulated by the rotational motion of the 
vessel maintaining cells in a constant state of free fall, similar to what astronauts 
experience in orbit around Earth. The RCCS has been used to simulate microgravity in a 
variety of cell types, including lymphocytes, osteoblasts, and myoblasts[57–59]. The 
C2C12 cell line used in the experiment presented herein is a mouse myoblast line that can 
differentiate into contractile skeletal muscle fibers. First cultured in 1977, the C2C12 cell 
line produces many of the same proteins as human muscle tissue, making it a suitable 
analog for investigation of radiation and atrophic conditions[60]. 
Harmful radiation in space primarily comes in two forms, gamma rays and high 
energy heavy ions[20]. Radiation intensity fluctuates depending on solar activity and 
proximity to the Earth. The lowest radiation dose rates occur when in close proximity to 
the Earth and during the solar maximum[20]. Gamma rays are a form of electromagnetic 
radiation with no mass while high energy heavy ions are atomic nuclei stripped of 
electrons and moving at relativistic velocities. Some high energy heavy ions are produced 
by the Sun, but most come from distant supernovae.  
Relative biological effectiveness (RBE) is a measure of how damaging a 
particular type of radiation is to living tissue. Gamma radiation is assigned an RBE of 1 




indicating significantly more tissue damage for an equivalent dose[21]. Although high 
energy heavy ions present a greater health hazard in spaceflight, they are difficult to 
simulate in a laboratory and require large particle accelerators to produce.  In contrast, 
gamma radiation sources are relatively inexpensive and a large body of data exists 
regarding epidemiological studies in radiation-exposed humans, rodents, and non-human 
primates. 
NASA limits astronaut radiation exposure to levels that correspond with a 3% 
increase in fatal cancer risk[22]. Long term missions beyond low Earth orbit, such as a 
journey to Mars, exceed this limit within a single mission and increase the risk of 
developing cancer[20]. Due to the highly penetrating nature of high energy ions in 
cosmic radiation, shielding the spacecraft is not economically feasible[20]. Biological 
countermeasures to radiation damage and increased cancer risk provide an attractive 
alternative to heavy and costly shielding. 
One cellular response that counters radiation damage is the up-regulation of heme 
oxygenase-1 (HO-1)[23, 24]. HO-1 is induced in response to oxidative stress and 
combats this stress in part by degrading heme into biliverdin-IXα, a natural antioxidant 
and anti-inflammatory[25]. Artificial induction of HO-1 has demonstrated protective 
effects against ionizing radiation in multiple tissue types[24, 26]. We hypothesize that the 
cytoprotective effects of HO-1 are due to downstream biliverdin production from heme 
catabolism and activation of the phosphatidylinositol 3-kinase (PI3K)-Akt pathway by 
the biliverdin reductase cell surface receptor. An alternative treatment could include 
supplementation with vitamin E, which attenuates radiation-induced cell death and 






C2C12 cell stocks were maintained in their undifferentiated state with Dulbecco's 
Modified Eagles Medium (DMEM) and 10% fetal bovine serum (FBS) from HyClone, 
GE Healthcare. At passage 7, cells were seeded into the RCCS and control conditions at 
2.5x105 cells/mL. Culture conditions were maintained at 37°C and 5% CO2. Cell 
counting was performed with a Beckman Coulter ViCell, which uses a Trypan blue 
exclusion assay. The cells were seeded into DMEM 10% FBS. Every 3 days, the culture 
media was changed for fresh media. On day 6, the media was changed to DMEM 2% 
FBS to promote differentiation of the myocytes into myotubes. Experimental cultures 
were maintained for a total of 15 days. Experimental conditions were normal gravity, 
normal gravity with radiation, simulated microgravity, and simulated microgravity with 
radiation. Each condition was cultured in duplicate. 
 Microgravity Simulation 
A Synthecon RCCS-4H with four 10 mL high aspect ratio vessels (HARVs) was 
used to generate simulated microgravity conditions [Figure 13A]. Cells were cultured on 
5 mg/mL of HyClone HyQ Sphere Pplus 102-L microcarrier beads. Rotation of the 
culture vessels was maintained at 10-12 RPM to prevent settling and maintain cells in a 
constant state of free-fall. Microcarrier beads in Corning ultra-low attachment tissue 
culture flasks provide a normal-gravity control. Shear effects from media flow in the 
RCCS are accounted for by placing the control conditions on an orbital shaker plate at am 





Figure 13. Model setup for microgravity and spaceflight radiation simulation. A – Rotary 







Gamma radiation was provided by two Spectrum Technologies cesium-137 
source disks attached to the vessels for the duration of the culture [Figure 13C]. The 
radioactive source disks were approximately 10 µCi, calibrated to ± 5% according to the 
National Institute of Standards and Technology. Dose rate to the cells was 25-30 µSv/hr. 
Lead shielding with a thickness of 1.9 cm isolated control conditions from irradiated 
conditions, reducing dose rate to 0.5-1 µSv/hr [Figure 13D]. Cumulative dose for the 15 
day culture was approximately 10 mSv, equivalent to 24 days on the International Space 
station[76]. 
Spent Media Analysis 
Amino acid concentrations in cell culture media from day 15 were determined 
with a Waters Alliance 2695 high performance liquid chromatography (HPLC) system. 
Analysis of alanine and the branch chain amino acids (BCAAs) leucine, isoleucine, and 
valine was conducted. Alanine is secreted into the bloodstream by muscle fibers while 
BCAAs are oxidized for nutrients[74, 75]. Lower alanine and BCAA consumption would 
indicate decreased metabolic activity, expected in simulated microgravity and irradiated 
conditions. 
 Fluorescent Imaging 
Cell morphology, viability, lipid peroxidation, and DNA damage were determined 
via fluorescent imaging with a Zeiss confocal microscope. We expect decreased viability, 
increased lipid peroxidation from ROS, and double-strand DNA breaks in irradiated 
conditions. Simulated microgravity it expected to increase lipid peroxidation due to ROS. 




incubated with the dyes for 30 minutes at 37°C before imaging. Live cell imaging for 
viability used 1 µM Hoechst 33342, 2.5 µM propidium iodide, and 3 µM Calcein-AM. 
Live cell imaging for lipid peroxidation used 1 µM Hoechst 33342, 50 nM MitoTracker 
CMX-Ros, and 20 µM dichloro-dihydrofluorescein (DCF).  
For the fixed cell DNA damage H2AX assay, cells were first incubated in DMEM 
with 50 nM Mitotracker CMX-Ros for 30 minutes at 37°C. The media was removed and 
PBS containing 4% paraformaldehyde was added for 15 minutes at room temperature to 
fix the cells. The cells were rinsed once with PBS and then permeabilized with 2.5 
µL/mL of Triton X-100 in PBS for 15 minutes at room temperature. The fixation buffer 
was removed, the cells rinsed again in PBS, and then blocked for one hour with 10 
mg/mL of bovine serum albumin in PBS at room temperature to prevent non-specific 
binding of the primary antibody. After removing the blocking buffer, the 2 µg/mL of 
Anti-phospho-Histone H2AX (Ser139) primary antibody from Millipore, diluted in 
blocking buffer, was added for one hour at room temperature. The cells were then rinsed 
three times with PBS before adding 1 µg/mL of goat anti-mouse IgG (H+L) secondary 
antibody conjugated with Alexa Fluor 488, from Thermo Fisher Scientific. The 
secondary antibody was diluted in blocking buffer, along with Hoechst 33342, and 
incubated for one hour at room temperature. Finally, the cells were rinsed again three 
times with PBS and imaged. 
Western Blot 
Protein analysis was accomplished using Western blot. Lower concentrations of 
the muscle proteins myosin and tropomyosin are expected in simulated microgravity and 




adhered to the microcarrier beads. Cells were rinsed with PBS and lysed using a urea 
based lysis buffer containing 8M urea, 300mM NaCl, 5mL/L Triton X-100, 50mM 
sodium phosphate dibasic, and 50mM Tris-HCl. A protease inhibitor cocktail consisting 
of 1mM PMSF and 0.1mg/mL of pepstatin, antipain, and leupeptin was added to the lysis 
buffer. 
Lysate protein content was determined using a Pierce BCA protein assay kit and a 
Thermo Scientific NanoDrop. SDS PAGE was performed using pre-cast 4-20% Tris-
Glycine gels from NuSep. 20 µg of each sample was loaded onto the gel along with 10 
µg of actin and myosin standard from BioRad. After running at 150 V for one hour, the 
proteins were transferred to a PVDF membrane using a Pierce fast semi-dry blotter 
according to the manufacturer instructions. Primary antibodies MF-20 and CH-1, which 
have activity against myosin and tropomyosin, respectively, were purchased from the 
Developmental Studies Hybridoma Bank. Antibody concentration was 0.35 µg/mL. 
Antibody incubation was performed according to published protocol[77]. The blot was 
developed with SuperSignal West Pico Chemiluminescent substrate from Thermo 
Scientific and imaged with a Thermo Scientific myECL imager. 
Enzyme Linked Immunosorbent Assay 
HO-1 was assayed with an IMMUNOSET HO-1 (mouse) ELISA development set 
from Enzo Life Sciences. From the cell lysate, 20 µg of total protein, as determined by 
BCA assay, was loaded into each well. The plate was developed with 1-Step Turbo 






Results and Discussion 
Spent Media Analysis 
Slight decreases in alanine concentration for radiation exposed conditions were 
observed [Figure 14]. Alanine is not present in DMEM and is released by muscle fibers 
into the media as part of the alanine cycle[74]. Reduced alanine secretion indicates fewer 
muscle fibers and/or lower metabolic activity, expected for cells under increased stress or 
atrophic conditions. Reduced alanine in radiation exposed conditions was in line with 
expectations. On the other hand, alanine concentrations in simulated microgravity vs. 
normal gravity controls did not follow the expected trend. Cells cultured in simulated 
microgravity had higher extracellular alanine concentrations than the normal gravity 




Figure 14. Alanine concentrations in spent media harvested on day 15. NG = normal 
























No significant differences were observed in the concentration of BCAAs. BCAAs 
are oxidized during muscle fiber activity[75]. We expected to observe decreased BCAA 
consumption in conditions exposed to simulated microgravity. Similar BCAA 
consumption across all conditions may be due to insufficient sample size and/or culture 
time. 
Fluorescent Imaging 
Fluorescent imaging for cell viability did not reveal significant differences 
between conditions. Differentiation of myocytes into multi-nucleated myotubes was 
confirmed for all conditions, demonstrating that simulated microgravity does not prohibit 
formation of new muscle fibers. Lipid peroxidation was observed in both normal gravity 
controls and simulated microgravity conditions, as indicated by DCF [Figures 15-16]. 
Radiation provided by the cesium-137 sources induced minor double-strand DNA breaks, 
as visualized by H2AX phosphorylation[78] [Figures 17-18]. Stronger radiation sources 













Figure 15.  Normal gravity control stained 
for nuclei with Hoechst (blue), muscle fibers 
with MitoTracker (red), and lipid 
peroxidation with DCF (green). 
 
 
Figure 16.  Simulated microgravity control 
stained for nuclei with Hoechst (blue), 
muscle fibers with MitoTracker (red), and 
lipid peroxidation with DCF (green). 
 
Figure 17. No-radiation control under 
normal gravity stained for nuclei with 
Hoechst (blue), muscle fibers with 
MitoTracker (red), and H2AX 
phosphorylation (green, not present). 
 
 
Figure 18. Radiation exposed condition 
under normal gravity stained for nuclei with 
Hoechst (blue), muscle fibers with 
MitoTracker (red), and H2AX 







Enzyme Linked Immunosorbent Assay for Heme Oxygenase-1 
HO-1 is upregulated during periods of oxidative stress to catabolize heme into biliverdin, 
a natural antioxidant[79]. Due to oxidative stress induced by radiation and the microgravity 
environment, we expected to observe an increase in HO-1 for radiation-exposed conditions as 
well as cell cultured in simulated microgravity. However, decreased HO-1 in cell lysate was 
observed for radiation-exposed conditions [Figure 19]. The large error bars preclude drawing 
conclusions regarding HO-1 in simulated microgravity vs. normal-gravity controls until more 
data is generated. To maximize protein concentration, undiluted lysate was used for the assay. 




Figure 19. HO-1 ELISA with cell lysate containing 20 µg total protein. NG = normal gravity. 



















Proposed Atrophy and Radiation Countermeasures 
Successful development of a ground-based model for microgravity-induced muscle 
atrophy and spaceflight radiation would provide a low-cost platform for testing anti-atrophy and 
radioprotective drugs. We have identified promising therapeutic compounds to counter cellular 
damage from spaceflight conditions. A major contributor to muscular atrophy is the increased 
production of tissue-damaging reactive oxygen species following immobilization or disuse, 
including disuse stemming from the microgravity conditions of spaceflight[80–82]. Hydrogen 
peroxide (H2O2) released from murine mitochondria nearly doubles after two weeks of hind limb 
suspension, which in addition to its inherent cytotoxic effects stimulates the release of calpain 
and Caspase 3, proteases that degrade myofilaments[83]. Exposure to ionizing radiation also 
generates reactive oxygen species via radiolysis of water[19]. Scavenging these reactive oxygen 
species would limit calpain and Caspase 3 activation and protect cells from damage.  
Mesobiliverdin-IXα 
To combat the oxidative stress associated with disuse atrophy of skeletal muscle, we 
propose mesobiliverdin-IXα, a microbial-sourced analog of biliverdin-IXα with antioxidant and 
anti-inflammatory properties. Biliverdin-IXα cannot be economically extracted from mammalian 
cells due to rapid conversion to bilirubin by biliverdin reductase. However, we have isolated 
gram quantities of mesobiliverdin-IXα from cyanobacteria bile pigments using a scalable 
process. Mesobiliverdin-IXα was found to behave similarly to biliverdin-IXα, including serving 
as a substrate biliverdin reductase in human cells[84]. Cytoprotective effects of mesobiliverdin-
IXα and biliverdin analogs have been demonstrated with pancreatic islet cells, vascular 




Our preliminary data indicates increased protein production in both normal gravity and 
simulated microgravity conditions for cells supplemented with 10 µM of mesobiliverdin-IXα, as 
determined by Western blot [Figure 20]. The normal gravity control in this example performed 
worse than expected, likely due to mechanical stress from a rocker plate. Current controls are 
cultured on an orbital shaker with a fluid motion more similar to that of the RCCS. 
 
 
Figure 20. A – Myosin and tropomyosin standard. B – Normal gravity control. C – Normal 
gravity control with 10 µM mesobiliverdin-IXα. D – Microgravity control. E – Microgravity 
with 10 µM mesobiliverdin-IXα. 
 
The direct antioxidant properties of bilirubin and biliverdin-IXα in cell-free systems have 
been established[87]. We hypothesize that mesobiliverdin-IXα will exhibit indirect 
cytoprotection by moderating expression of heme oxygenase-1, an inducible enzyme which 




influence of mesobiliverdin-IXα on HO-1 is critical due to the numerous downstream effects of 
HO-1 activation. Increasing HO-1 expression with hemin supplementation attenuates 
immobilization-induced skeletal muscle atrophy, potentially by preventing protein degradation 
from oxidative stress[88].  
However, not all of the products of heme degradation are beneficial. In addition to 
biliverdin-IXα, heme degradation also results in the production of carbon monoxide (CO) and 
iron (Fe2+) [Figure 21]. Contrary to the antioxidant properties of biliverdin-IXα, free Fe2+ can 
react with H2O2 to produce a hydroxyl radical[18]. Furthermore, CO inhibits CCAAT-enhancer-
binding protein δ from binding to the MyoD promoter [Figure 21], thereby reducing the 
differentiation of myoblasts into contractile myotubes[89]. This side effect of the HO-1 oxidative 
stress response mechanism is especially detrimental in spaceflight, where significant muscle loss 
is experienced despite the current International Space Station exercise program[90].  
 
 




Mesobiliverdin-IXα may provide the cytoprotective effects of HO-1 without induction of 
MyoD inhibition and Fe2+ generation. Activation of cell-surface biliverdin reductase (BVR) has 
important downstream consequences, inducing Akt via intracellular phosphorylation of BVR, 
which binds to the p85α subunit of PI3K[91]. PI3K activation suppresses phosphatase and tensin 
homolog (PTEN), a negative regulator of muscle growth[92]. Furthermore, Akt regulated protein 
synthesis pathways are inhibited during periods of inactivity[92]. Activation of the PI3K-Akt 
pathway also limits cellular apoptosis following irradiation[93, 94]. Since mesobiliverdin-IXα 
serves as a substrate for human BVR[84], we hypothesize that supplementation with 
mesobiliverdin-IXα will provide the benefits of increased PI3K and Akt expression. The 
prospective action of mesobiliverdin-IXα through the BVR—PI3K—Akt pathway is 
encouraging. Activating Akt directly causes feedback inhibition of PI3K, associated with cardiac 
dilation and death in the long-term[95, 96]. Since mesobiliverdin-IXα’s action on Akt would be 
indirect, we do not anticipate the aforementioned complications. 
It will be critical to determine if mesobiliverdin-IXα inhibits HO-1 via a feedback 
mechanism. The breakdown of heme is important, as excess heme produces inflammation and 
apoptosis in a variety of cell types[97, 98]. If, upon mesobiliverdin-IXα supplementation, HO-1 
induction is lessened in response to oxidative stress but not in response to free heme, MyoD-
inhibiting CO and generation of hydroxyl radicals from Fe2+ will be limited while both the direct 
antioxidant properties of mesobiliverdin-IXα and downstream BVR—PI3K—Akt pathways are 
maintained. 
Vitamin E 
Another promising atrophy and radiation countermeasure is vitamin E. The antioxidant 




and -12, reducing muscular atrophy due to immobilization and unloading[27, 28]. In addition to 
preventing muscle loss, vitamin E also preserves bone mass and strength following 
unloading[29]. Several forms of vitamin E have  demonstrated radioprotective effects, including 
α-tocopherol, δ-tocotrienol, and γ-tocotrienol[30–32]. Unlike mesobiliverdin-IXα, vitamin E 
inhibits the PI3K-Akt pathway, which may promote apoptosis of tumor cells[99, 100]. The 
effects of combined mesobiliverdin-IXα and vitamin E supplementation will also be 
investigated. 
Conclusions 
The RCCS successfully cultures and permits differentiation of multi-nucleated myotubes, 
basic components of muscle tissue. Irradiation for 15 days with 20 µCi of cesium-137 produces 
minimal double-stranded DNA breaks. Exposure to radiation resulted in decreased 
concentrations of alanine and HO-1, though more data must be generated to determine statistical 
significance. Stronger radiation sources are being investigated to provide a dose equivalent to a 
journey to Mars within a two week culture period.  
The initial data generated since January 2015 are insufficient to determine whether or not 
the combination of a RCCS and radiation source provide a platform that generates conditions 
mimicking spaceflight. To conclusively demonstrate similarity of the model to spaceflight, 
muscle protein concentration must be lower and markers of oxidative stress must be higher in 
microgravity and irradiated conditions. Increased expression of the atrophy markers Atrogen-1, 
MuRF1, and Nedd4 in simulated microgravity would provide evidence of the model’s 
effectiveness[101]. Analysis of these markers with qRT-PCR is ongoing. Culture on flat 




required for 3D bead clusters can take more than one hour per image, leaving ample time for 
cells to undergo changes when performing live cell imaging. 
Completion of an in vitro ground-based model for spaceflight atrophy and radiation 
injury would provide a valuable platform for testing countermeasures necessary to ensure 
astronaut health and fitness during long-term spaceflight. Radiation doses can be tuned to 
simulate a variety of mission circumstances from short-term low Earth orbit to multi-year 
expeditions on Mars. The metrics presented herein will also elucidate the mechanisms of action 
for atrophy and radiation countermeasures, providing a foundation for design and selection of 




















Muscle atrophy marker expression differs between rotary cell culture system and animal studies 
 
Abstract 
 Muscular atrophy, defined as the loss of muscle tissue, is a serious issue for immobilized 
patients on Earth and in human spaceflight, where microgravity prevents normal muscle loading. 
In vitro modeling is an important step in understanding atrophy mechanisms and testing 
countermeasures before animal trials. The most ideal environment for modeling must be 
empirically determined to best mimic known responses in vivo. 
 To simulate microgravity conditions, murine C2C12 myoblasts were cultured in a rotary 
cell culture system (RCCS). Alginate encapsulation was compared against polystyrene 
microcarrier beads as a substrate for culturing these adherent muscle cells. Changes after culture 
under simulated microgravity were characterized by assessing mRNA expression of MuRF1, 
MAFbx, Caspase 3, Akt2, mTOR, Ankrd1, and Foxo3. Protein concentration of myosin heavy 
chain 4 (Myh4) was used as a differentiation marker. Cell morphology and substrate structure 
were evaluated with brightfield and fluorescent imaging. 
 Differentiated C2C12 cells encapsulated in alginate had a significant increase in only 
MuRF1 following simulated microgravity culture and were morphologically dissimilar to normal 
cultured muscle tissue. On the other hand, C2C12 cells cultured on polystyrene microcarriers had 
significantly increased expression of MuRF1, Caspase 3, and Foxo3 and easily identifiable 
multi-nucleated myotubes. The extent of differentiation was higher in simulated microgravity 




microcarrier model described herein significantly increases expression of several of the same 
atrophy markers as in vivo models. However, unlike animal models, MAFbx and Ankrd1 were 
not significantly increased and the fold change in MuRF1 and Foxo3 was lower than expected. 
Using a standard commercially available RCCS, the substrates and culture methods described 
only partially model changes in mRNAs associated with atrophy in vivo.  
Introduction 
Muscle loss from disuse negatively affects quality of life in patients on Earth and remains 
a significant risk factor to astronaut health despite rigorous exercise programs onboard the 
International Space Station[102, 8]. Approximately 40-50% of total body mass is skeletal muscle 
and its loss can induce numerous detrimental physiological changes, including reduced power, 
lower endurance, and atypical reflex responses[6, 7]. Disuse, reduced protein synthesis, and 
reduced motor neuron activity all contribute to losing muscle tissue and strength in 
spaceflight[6]. Atrophy severity varies with microgravity exposure time and anatomical region. 
Muscle mass loss for short duration missions ranges from 10-20%, compared to 30-50% for long 
duration missions[2, 3]. To reduce these risks, flight protocol at the National Aeronautics and 
Space Administration (NASA) mandates that crew members exercise on missions lasting over 10 
days; however, loss of strength and muscle mass has been reported after only 5 days[4, 5]. 
Preserving astronaut strength and endurance by limiting muscle atrophy is critical for enabling 
long duration space travel and exploration. To this end, ground-based modeling of microgravity 
is a critical step in developing atrophy countermeasures. 
Three key mRNAs in muscle loss are muscle RING finger-1 (MuRF1, also called 
Trim63), muscle atrophy F-box (MAFbx, also called Fbxo32 and Atrogin-1), and Caspase 3, all 




hind limb unloading, as well as spaceflight[12, 15, 34–45]. MuRF1 and MAFbx are key E3 
ubiquitin ligases involved in recycling of muscle proteins[12]. However, intact muscle fibers 
cannot be degraded by the ubiquitin proteasome system and must be broken down before MuRF1 
and MAFbx can act. This breakdown is induced by Caspase 3, upregulated during muscular 
atrophy and responsible for the degradation of actomyosin complexes in the muscle tissue[7, 11]. 
Following hind limb unloading, knockout mice lacking MuRF1 and MAFbx display significantly 
less atrophy than wild type mice, highlighting the importance of those ligases in the mechanisms 
underlying muscle loss[12, 35]. 
Additional mRNAs important for monitoring muscle health include Akt2, Foxo3, mTOR, 
and Ankrd1. Akt2 (also called Protein Kinase B β) is a serine/threonine-protein kinase and a 
downstream target of insulin-like growth factor (IGF) induced muscle differentiation[103]. 
Upregulated significantly in differentiated skeletal muscle, the absence of Akt2 leads to a 
substantial reduction in myotube diameter[104]. Forkhead Box O3 (Foxo3), another downstream 
target of the IGF signaling pathway, is also upregulated during muscle atrophy in vitro and in 
vivo[105–107]. Foxo3 is responsible for activation of multiple atrophy-related transcription 
factors, including the ubiquitin ligase MAFbx[107]. A third component of the IGF signaling 
pathway is mammalian target of rapamycin (mTOR), a regulator of protein synthesis and muscle 
hypertrophy that is increased by mechanical stimulation and in the presence of nutrients and 
growth factors[108, 109]. Unlike the previously discussed mRNAs, mTOR expression decreases 
during muscle atrophy as the ubiquitin proteasome system becomes more active.  
Finally, cardiac ankyrin repeat protein (Ankrd1, also called CARP) is upregulated in both 
unloading and denervation models in vivo[106, 110]. The increase in Ankrd1 expression during 




markers such as MAFbx and MuRF1[110]. Furthermore, the aforementioned proteasome-related 
markers may only be temporarily upregulated during the initial stages of muscle atrophy, where 
Ankrd1 is persistently expressed at high levels[110]. The large, easily detected increase in 
Ankrd1 makes it an attractive target for evaluating muscular atrophy models. 
A classic method for simulating weightlessness is the hind limb unloading rodent model, 
developed at NASA in the 1970’s[33]. In this model, the rodent is affixed in a harness or tail 
traction device such that the hind limbs are elevated at a 30° angle[33]. The resulting unloading 
induces muscle atrophy in the hind limbs and cephalic fluid shift similar to real microgravity 
conditions[33]. However, ground-based animal models differ from human physiology, are more 
time consuming, more expensive, and are subject to more regulation than cell culture models, 
providing strong motivation to develop other methods. Newly developed therapeutics can be 
effectively screened with smaller quantities in cell culture models and safe dose ranges 
established prior to testing in vivo. Highly tissue-specific effects can be elucidated without 
confounding variables introduced by other systems in the organism. Additionally, cell culture 
models enable use of primary human cell lines, increasing biological relevance to humans. 
In vitro modeling of microgravity can be conducted with rotary culture systems and 
three-dimensional random positioning machines or clinostats[54, 55]. Here, we employ the 
RCCS, developed by Synthecon Inc. in conjunction with NASA to simulate microgravity[54]. In 
the RCCS, microgravity is mimicked by the rotational motion of the vessel maintaining cells at 
their terminal settling velocity, similar to what astronauts experience in orbit around Earth. The 
RCCS has been used to simulate microgravity in a variety of cell types, such as lymphocytes, 
osteoblasts, and myoblasts, including the C2C12 mouse myoblast cell line used herein[56–59, 




many of the same proteins and mRNAs as human muscle tissue[60]. Use of a mouse cell line for 
in vitro model development and extension also benefits from a large body of literature available 
on mRNA expression in live mouse microgravity models, providing information for evaluating 
the model’s similarity to in vivo studies. Previously published work with muscle cells, including 
C2C12s, in simulated microgravity focused on changes in differentiation induced by culture in 
the RCCS[56, 59, 73]. To the best of the authors’ knowledge, no previously published work has 
investigated changes in atrophy-specific mRNAs with muscle cell culture in the RCCS.  
Standard culture methods for adherent cells in the RCCS employ a substrate to support 
growth. Two substrates commonly used in three-dimensional cell culture are microcarrier beads 
and alginate encapsulation. Microcarriers are an attractive substrate due to ease of scalability for 
producing large quantities of cells for therapeutic applications[69, 70]. As in standard tissue 
culture flasks, C2C12 cells differentiate on microcarriers in vitro.  The beads offer a wide variety 
of surface chemistries tailored to specific cell types and culture conditions[69]. 
Alternatively, adherent cells can be encapsulated within a several synthetic or naturally 
occurring hydrogels[61]. Naturally occurring alginate hydrogel has well established uses for 
mammalian cell encapsulation due to low toxicity and gentle gelling conditions[61–66]. 
Additionally, the high porosity of alginate hydrogels is advantageous for maximizing diffusion 
rates and ensuring adequate exchange of nutrients and waste products with the surrounding 
culture media[62]. In contrast with microcarrier beads, which can only be seeded with 
undifferentiated cells, alginate encapsulation can be performed on both undifferentiated and 
differentiated muscle cells. The percentage alginate used for encapsulation can be varied 




To preserve bead integrity in the dynamic RCCS environment, we elected to encapsulate cells at 
the upper end of this range to maximize mechanical strength of the beads[62]. 
Here, we propose a ground-based protocol using C2C12 cells and a RCCS to induce 
expression of the atrophy-related mRNAs MuRF1, Caspase 3, and Foxo3. Additionally, the 
model induces significant changes in Akt2 and mTOR expression. The model is limited by a lack 
of significant MAFbx and Ankrd1 expression and low fold changes in MuRF1 and Foxo3. While 
not currently suitable for these purposes, with further development we expect that the RCCS can 
be improved to more closely match the expression changes of animal hind limb unloading 
models. 
Materials and Methods 
Cell Culture 
C2C12 (ATCC CRL-1772, Manassas, VA, USA) cell stocks were maintained in their 
undifferentiated state with Dulbecco's Modified Eagles Medium (DMEM) and 10% fetal bovine 
serum (FBS) from HyClone, GE Healthcare (Logan, UT, USA). Stocks were passaged at 60-
70% confluency during scale-up. Cell counting prior to seeding was performed with a Beckman 
Coulter Vi-Cell (Indianapolis, IN, USA), which uses a trypan blue exclusion assay. The 
experimental conditions consisted of four replicated vessels per run for each condition described 
in Table 1. Controls consisted of standard T25 tissue culture flasks for alginate encapsulated 
conditions and ultra-low attachment (ULA) tissue culture flasks (Corning, NY, USA) for 
microcarrier conditions. 
Table 1. Experimental conditions. All cultures had a total duration of 15 days. 
Substrate Cell State at Seeding Culture Vessel 
Alginate Undifferentiated Standard T25 (Control) 
Alginate Undifferentiated RCCS 




Alginate Differentiated RCCS 
Microcarrier Undifferentiated ULA T25 (Control) 
Microcarrier Undifferentiated RCCS 
Microcarrier Undifferentiated Horizontally orientated RCCS (Control) 
Microcarrier Undifferentiated ULA T25 Days 1-12, RCCS Days 13-15 
 
The use of ultra-low attachment flasks for microcarrier cultures was necessary to prevent 
cells from growing on the flask surface, forcing adherence on the microcarrier beads and 
ensuring the available surface area for cell growth was identical to the RCCS vessels. Cells were 
seeded into each experimental condition of Table 1 at 2.5x105 cells mL-1 with a total volume of 
10 mL. Culture conditions were maintained at 37°C and 5% CO2. Every 3 days, the culture 
media was changed for fresh media. On day 6, the media was changed to DMEM 2% FBS to 
promote differentiation of the myocytes into myotubes. All cultures were maintained for a total 
of 15 days. The 15 day culture time was selected to maximize exposure to the simulated 
microgravity environment while preventing loss of cell attachment from microcarriers, 
previously reported for longer duration cultures[112]. For the final condition in Table 1, the cells 
were moved from ULA T25s to the RCCS for the final 3 days of the culture period. 
Microgravity Simulation 
A Synthecon RCCS-4H (Houston, TX, USA) with four 10 mL high-aspect-ratio vessels 
(HARVs) was used to generate simulated microgravity conditions. Sterilization and operation of 
the Synthecon RCCS-4H was carried out in accordance with the manufacturer’s instructions. 
Vessel rotation was adjusted empirically to maintain the majority of the substrate in suspension, 
as described in Table 2. The horizontally orientated RCCS, investigated as a normal gravity 
control, was maintained at the mean RPM of 15. When the substrates are maintained at their 




𝐹𝑔 = (𝜌𝑎 − 𝜌)𝑔
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𝜋𝑅3    (1) 
In Equation 1, 𝜌𝑎 is the density of the cell aggregate, 𝜌 is the density of the culture media, 𝑅 is 
the radius of the cell aggregate and 𝑔 is the force of gravity. The resulting 𝐹𝑔 is balanced by the 
drag force from the rotating fluid, resulting in a net force of zero. Since 𝑔 and 𝑅 are constant at 
any given moment, the ratio of 𝐹𝑔 in the RCCS to the normal force of gravity can be simplified to 
express how many times normal gravity (𝑋𝑔) is produced within the system, as described by 
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Table 2. The RCCS rotation rate necessary to maintain the substrates in suspension varies with 
diameter. Times Earth Gravity varies with substrate density. aMicrocarrier initial diameter at 
seeding. bMicrocarrier cluster diameter at harvest. Data displayed as mean ± CV, n=10. 
Substrate Density (g cm-3) 𝑋𝑔 Diameter (µm) RPM 
Microcarriers 1.02 0.02 160±18.7%a to 698±10.5%b 10-20 
Alginate 1.07 0.07 3252±3.2% 35 
 
Microcarriers 
Undifferentiated C2C12 cells were cultured on 5 mg mL-1 of HyClone HyQ Sphere Pplus 
102-L microcarrier beads. These polystyrene beads have a cationic surface charge and are well 
suited for culturing cells in agitated vessels with serum-containing media[69]. Rotation of the 
culture vessels was initiated at 10 RPM and increased up to 20 RPM as the culture age increased 
and amalgamations of beads formed. Vessel RPM was adjusted empirically to prevent settling 




ULA T25 tissue culture flasks provided a normal-gravity control and produced microcarrier 
cluster sizes similar to those in the RCCS. 
Alginate Encapsulation 
Undifferentiated C2C12 cells were mixed with 3% (w/v) solution of high viscosity 
alginate (MP Biomedicals, Santa Ana, CA, USA) at a density of 10x106 cells mL-1. Beads were 
formed by dripping the alginate-cell mixture into 200 mM CaCl2 10mM HEPES at pH 7 through 
a 19-gauge syringe needle at a flow rate of 2 mL min-1. The beads were cured in CaCl2 buffer for 
20 minutes at 37°C. Once cured, the average bead diameter was 3252±103 µm with a volume of 
approximately 18 µL, yielding 1.8x105 cells per bead. To match the seed volume of the 
microcarriers, 14 alginate beads were used per 10 mL vessel. The beads were rinsed once with 
DPBS and transferred to their respective culture conditions in DMEM 10% FBS.  
Differentiated cells were encapsulated following 9 days of growth in standard tissue 
culture flasks. The myotubes were removed from the flask with a cell scraper and re-suspended 
at a density of 75 cm2 culture area per mL of alginate. Subsequent alginate encapsulation 
methods were performed as described for undifferentiated cells. 
Upon harvest, the alginate beads were dissolved with 100 mM sodium citrate, 150 mM 
NaCl, 30 mM EDTA at pH 7.0 and 37°C. The cells were pelleted via centrifugation and rinsed 
with DPBS before proceeding with RNA extraction, as described in the following section. 
Atrophy Marker Expression 
Relative expression of the atrophy markers MuRF1, MAFbx, and Caspase 3 was 
determined using RT2 qPCR primer assays from Qiagen (Hilden, Germany). Akt2, mTOR, 
Foxo3, and Ankrd1 primers were purchased from Bio Rad (Hercules, CA, USA). RNA 




according to the manufacturer’s instructions (GE Healthcare, Marlborough, MA, USA). 
Extracted RNA was quantified with a NanoDrop (Thermo Fisher Scientific, Waltham, MA, 
USA) and converted to cDNA with the RT2 First Strand Kit from Qiagen. All PCR reactions 
were loaded with 5 ng of cDNA and SYBR Green ROX qPCR Mastermix from Qiagen. 
Fluorescence was read with an Eppendorf Mastercycler realplex4 (Hamburg, Germany). Cycle 
settings were 95°C for 10 minutes, followed by 40 cycles of 95°C for 15 seconds, then 60°C for 
1 minute. Analysis was performed using the default noise band threshold with drift correction 
applied in Eppendorf Mastercycler realplex 2.2 software. All results were normalized to 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH), a suitable housekeeping gene for 
atrophying muscle tissue in vitro and in vivo[113–118]. GAPDH expression in our samples was 
stable, with a CV of 2.5% for all microcarrier samples and 3.7% for all alginate samples. 
Normalization was calculated with the 2ΔΔCt method[119]. 
Microscopy 
Brightfield microscopy was performed using an AMG EVOS xl from Thermo Fisher 
Scientific to assess encapsulated cell distribution and alginate bead size and shape. The beads 
were then fixed in cold methanol for 30 minutes at -20°C, transferred to a solution of 30% 
sucrose 0.1M CaCl2 overnight at 4°C, then frozen in Tissue-Plus O.C.T. compound (Fisher 
Scientific, Pittsburg, PA, USA) at -20°C until sectioning[120]. Using a Leica CM1850 cryo-
microtome (Wetzlar, Germany), the beads were sliced into 30 µm sections and mounted on 
Fisher SuperFrost Plus slides, treated with 1 µM Hoechst 33342 (Invitrogen, Carlsbad, CA, 





Cell morphology for microcarriers was also evaluated via fluorescent imaging with the 
Observer Z1 confocal microscope. Microcarrier-cell clusters were first rinsed with DPBS, then 
incubated with 1 µM Hoechst 33342 and 50 nM MitoTracker CMX-Ros (Invitrogen, Carlsbad, 
CA, USA) for 1 hour at 37°C. The clusters were rinsed again with DPBS and z-stack images 
were acquired with a 3 µm step size. Diameter of multi-nucleated muscle fibers growing on the 
microcarriers was determined with ImageJ. 
Protein Assay 
Extent of terminal differentiation was quantified by ELISA for mouse myosin heavy 
chain 4 (Myh4) (Biomatik, Wilmington, DE, USA), present in high levels in fused 
myotubes[121]. Cells were rinsed with PBS and lysed using a urea-based lysis buffer containing 
8 M urea, 300 mM NaCl, 5mL L-1 Triton X-100, 50 mM sodium phosphate dibasic, and 50 mM 
Tris-HCl. A protease inhibitor cocktail consisting of 1 mM PMSF and 0.1mg mL-1 of pepstatin, 
antipain, and leupeptin was added to the lysis buffer. The cells were lysed on the microcarriers 
and the lysate was isolated by centrifugation. Lysate protein content was determined using a 
BCA protein assay kit (Pierce, Rockford, IL, USA) and a SpectraMax i3x (Molecular Devices, 
San Jose, CA, USA). Lysates were diluted to 1 µg mL-1 total protein with PBS and the ELISA kit 
ran according to the manufacturer’s instructions. Quantitation was performed using the 
Spectramax i3x. 
Statistics 
 Graphical data are presented as the means ± standard deviation. Significance was 
determined by comparing data sets with Student’s t-test. Differences were considered significant 





Microcarrier Substrate Structure & Cell Morphology 
When cultured on HyQSphere Pplus 102-L microcarriers, C2C12 cells form monolayers 
over the bead surface (Figure 22). Differentiated, multi-nucleated myotubes were observed 
spanning across beads (Figure 22A, C). No significant difference was observed in differentiation 
or number of multi-nucleated myotubes between simulated microgravity and normal gravity 
controls. The irregular three-dimensional structure of the bead amalgamations was best 
visualized with brightfield microscopy (Figure 22B, D). Microcarrier bead cluster size increased 
with culture age in both normal gravity controls and simulated microgravity conditions. Due to 
the lack of agitation, maximum cluster size was larger in normal gravity controls than in the 
RCCS. Additionally, bead clusters formed in normal gravity had widely varying, irregular shapes 
compared to consistently rounded bead clusters formed in the RCCS (Figure 22 A, B vs. C, D). 
Despite variations in cluster size and shape, no significant differences in cell morphology were 
observed. Muscle fiber diameter was 12.7±6.0 µm and 9.5±1.7 µm for normal gravity controls 
and simulated microgravity conditions, respectively. Fiber diameters were more consistent in the 






Figure 22. Microcarrier bead clusters after 15 days of culture, imaged at 10x magnification. 
Nuclei are stained blue with Hoechst 33342. Mitochondria are stained red with MitoTracker 
CMX-Ros. Normal gravity (A, B) and simulated microgravity (C, D) bead clusters both have 






Alginate Substrate Structure & Cell Morphology 
Undifferentiated cells encapsulated in alginate were evenly distributed throughout the 
bead (Figure 23A), where encapsulation of differentiated cells resulted in irregular sheets with 
uneven distribution (Figure 23B). A section of an alginate bead containing differentiated cells 
reveals the encapsulation process forces the harvested muscle fibers into atypical configurations 
(Figure 23C), compared to the regular, parallel orientation common in standard tissue culture 
flasks (Figure 23D). For cells encapsulated in their undifferentiated state, minimal differentiation 
was observed after 15 days of culture. No differences in cell morphology were observed between 
the RCCS and normal gravity controls. Alginate bead degradation was minimal, as more than 







Figure 23. Alginate encapsulated undifferentiated (A) and differentiated cells (B) imaged at 2x 
magnification, scale bar = 1000 µm. Interior morphology of encapsulated differentiated cells in a 
30 µm section of an alginate bead (C) compared to a standard T25 (D), scale bar = 100 µm. 
Nuclei are stained blue with Hoechst 33342 (C & D). Mitochondria are stained red with 
MitoTracker CMX-Ros (D only). 
 
Atrophy Marker Expression 
Alginate-encapsulated differentiated cells in the RCCS expressed significantly more 
MuRF1 than those in T25s, but the difference in MAFbx and Caspase 3 expression was not 




less MuRF1, MAFbx, and Caspase 3 than those in T25s, contrary to the hypothesized response 
(Figure 24).  
When cultured on microcarriers, expression of MuRF1 and Caspase 3 was significantly 
elevated after 12 days in ULA T25s, followed by 3 days in the RCCS, relative to ULA T25 
control flasks (Figure 24). Cultures that remained in the RCCS for 15 days also expressed 
significantly more MuRF1 and Caspase 3 than the ULA T25 control. The change in MAFbx was 
not significant for either simulated microgravity culture method but was larger for the ULA T25 












Figure 24 Average ± s.d. fold change in expression of mRNAs for alginate and microcarrier 
cultures, relative to their respective normal gravity controls (alginate N=4, microcarrier N=20) 
and normalized by GAPDH. * p<0.05, ** p<0.01, *** p<0.001. No marker = not significant. 
N=4 (alginate differentiated), N=4 (alginate undifferentiated), N=16 (RCCS), and N=8 (ULA 












Table 3. Significance of microcarrier culture mRNA expression changes, as determined by 
Student’s t-test. N=20 for ULA T25, N=16 for RCCS, N=8 for ULA T25 + RCCS, and N=4 for 
Horizontal RCCS. ns = not significant, * p<0.05, ** p<0.01, *** p<0.001. All replicates are 
biological replicates. 
MuRF1 ULA T25 RCCS Horiz. RCCS ULA T25 + RCCS 
ULA T25 — *** *** ** 
RCCS *** — ns ** 
Horiz. RCCS *** ns — *** 
ULA T25 + RCCS ** ** *** — 
 
MAFbx ULA T25 RCCS Horiz. RCCS ULA T25 + RCCS 
ULA T25 — ns ns ns 
RCCS ns — ** *** 
Horiz. RCCS ns ** — *** 
ULA T25 + RCCS ns *** *** — 
 
Caspase 3 ULA T25 RCCS Horiz. RCCS ULA T25 + RCCS 
ULA T25 — *** *** *** 
RCCS *** — ns ns 
Horiz. RCCS *** ns — * 
ULA T25 + RCCS *** ns * — 
 
 Cells cultured in the RCCS for 15 days and those cultured in the RCCS for only 3 days 
following 12 days in ULA T25’s had similarly significant increases in the key atrophy markers 
MuRF1 and Caspase 3. Due to shorter duration of RCCS culture, using the latter method allows 
for higher throughput testing in a given timeframe, as subsequent cultures need only be staggered 
by 3 days instead of 15. Therefore, the ULAT25 + RCCS method was selected for further 
development of the model and evaluation of Akt2, mTOR, Ankrd1, and Foxo3. Akt2, mTOR, 
and Foxo3 increased significantly in simulated microgravity, but the change in Ankrd1 was not 





Figure 25. Average ± s.d. fold change in expression of mRNAs for ULA T25 + RCCS simulated 
microgravity cultures (N=8) relative to ULA T25 normal gravity control (N=20) and normalized 
by GAPDH. * p<0.05, ** p<0.01, *** p<0.001. All replicates are biological replicates and 
significance was determined by t-test. Change in MAFbx and Ankrd1 not significant. 
 
Protein Concentration 
Myosin heavy chain 4 (Myh4) was used to assess the extent of terminal differentiation. After 15 
days of culture on microcarriers in ULA normal gravity control flasks, Myh4 concentration was 
1.22±0.26 ng µg-1 total protein. Cells cultured in the RCCS for the final 3 days following 12 days 
in the ULA flasks had an Myh4 concentration of 2.13±0.48 ng µg-1 total protein. The difference 








We hypothesized that alginate encapsulated cells would exhibit more significant 
increases in atrophy marker expression than cells cultured on microcarriers, since an 
encapsulated three-dimensional mass of differentiated muscle tissue may exhibit greater inherent 
similarity to animal models than monolayers on the exterior of microcarriers. However, the 
alginate-encapsulated differentiated cells only exhibited an increase in MuRF1. Further, 
encapsulated undifferentiated cells had significantly lower expression of MuRF1, MAFbx, and 
Caspase 3 in simulated microgravity, which was the opposite of expected results (Figure 24). 
Low expression of atrophy markers for encapsulated undifferentiated cells may be due to 
insufficient myotube formation. The solid alginate structure limits cell-cell contact and 
morphology remained consistent over the 15 day culture period (Figure 23A). On the other hand, 
C2C12 cells cultured on polystyrene microcarrier beads for 12 days in ULA T25 flasks followed 
by 3 days in the RCCS significantly (p<0.05) express more MuRF1, Caspase 3, Akt2, mTOR, 
and Foxo3 than the normal gravity control of cells cultured in static ULA T25s for all 15 days, 
highlighting the early upregulation of these markers in simulated microgravity (Figure 24). 
The timing of maximum MAFbx and MuRF1 expression has in vivo remains under 
investigation. Elevated expression has been reported at 3 days, 7 days, and 6 weeks, though 
differences in animal line and immobilization methods may be responsible[42, 44, 45]. Unlike 
MAFbx and MuRF1, in vivo atrophy models produce consistent significant increases in Caspase 
3 over 5, 10, and 14 days[40, 41]. Our results in vitro indicate that MuRF1 expression is higher 
in cells cultured for 15 days in the RCCS, compared to 3 days in the RCCS after 12 days in ULA 
flasks, while Caspase 3 expression does not change significantly (Figure 24 & Table 3). We did 




suggesting that the timing of upregulation differs from its partner E3 ligase MuRF1. In addition 
to the uncertain timing of peak upregulation, this discrepancy in MuRF1 and MAFbx 
upregulation may be due to the different roles of the two ligases. While MuRF1 and MAFbx 
both play an important part in the ubiquitin proteasome system, MuRF1 is more closely 
associated with degradation of myofibers, where MAFbx attenuates new protein synthesis and is 
not correlated with atrophy in every case[122, 123]. 
Increased expression of Akt2 and higher Myh4 concentrations in simulated microgravity 
indicate a higher percentage of differentiated cells compared to the normal gravity controls. 
mTOR, expected to be lower in simulated microgravity, instead increased significantly after 3 
days in the RCCS (Figure 25). Additionally, while Foxo3 will activate MAFbx, Foxo3 was 
significantly upregulated while MAFbx—responsible for attenuating protein synthesis—was not 
(Figure 25) [107, 122]. Taken together, these results indicate that while the cells in simulated 
microgravity were undergoing atrophy—indicated by MuRF1, Caspase 3, and Foxo3—mTOR 
mediated protein synthesis and formation of new myotubes had not yet ceased. 
Compared to in vivo methods, including casting, tenotomy, and hind limb unloading, our 
in vitro model resulted in a similar fold change in Caspase 3 and lower but still statistically 
significant increases in MuRF1 and Foxo3 (Table 4). While Caspase 3 is most strongly 
upregulated, apoptosis from shear forces is not likely due to the low shear environment of the 
RCCS[54].  The fold increase in MuRF1 after 12 days in normal gravity and 3 days in the RCCS 
was closer to that of 3 days post-tenotomy rather than 3 days post-immobilization via casting 
(Table 4). The in vitro model did not significantly increase MAFbx, but again the fold change 




our in vitro model did not produce any significant changes (Table 4). While Ankrd1 is expressed 
in C2C12 cells, it was not significantly upregulated in this model[124, 125]. 
 
Table 4. Fold change in gene expression of atrophy-indicating mRNAs from this in vitro study 
(ULA T25 12 days + RCCS 3 days) compared to referenced work in vivo, as measured by qPCR. 
ns = not significant, ** p<0.01, *** p<0.001. 
 In Vitro In Vivo In Vivo method 
MuRF1 1.3** 1.9, 1.6[45] Casting 3 days, tenotomy 3 days 
MAFbx 1.3ns 2.7, 1.5[45] Casting 3 days, tenotomy 3 days 
Caspase 3 3.8*** 1.0, 3.3[45] Casting 3 days, tenotomy 3 days 
Ankrd1 1.1ns 3.9[106] Hind limb unloading 6 days 
Foxo3 1.4** 1.6[106] Hind limb unloading 6 days 
 
Turning the RCCS horizontal was investigated as a normal gravity control to account for 
the effects vessel geometry and fluid motion not present in static ULA tissue culture flasks. 
Despite these benefits, the horizontal RCCS was an ideal control due to significant differences in 
microcarrier bead cluster morphology and higher MuRF1 expression levels compared with the 
simulated microgravity conditions (RCCS, ULA T25 + RCCS) (not shown). Additionally, 
microcarrier beads in the horizontal RCCS adhered to the silicone gas transfer membrane, 
resulting in large sheets of cells not representative of the bead clusters in Figure 22. Shear forces 
from fluid motion in the RCCS are minimal and selecting a control with similar cluster 
morphology and consistently significant differences in mRNA expression is preferred[54]. 
Microcarrier beads and alginate encapsulation each have advantages and disadvantages in 
maximizing similarity with in vivo hind limb unloading methods. The advantages of 
microcarriers include ease of handling, live cell fluorescent imaging capability, and most 




microcarrier beads are simpler and more rapid than alginate encapsulation. The small size of the 
beads allows them to be transferred between containers via pipette. Harvest of RNA can be 
accomplished by adding the cell-covered microcarriers directly to the lysis buffer, reducing 
process time and opportunity for RNase activity. Most critically, simulated microgravity culture 
of C2C12 cells on microcarriers resulted in significant expression changes in multiple atrophy 
markers compared to the normal gravity control (Figure 25).  However, MAFbx and Ankrd1 
were not significantly upregulated and the fold increase in MuRF1 and Foxo3 were low, 
indicating that this model is incomplete when compared to atrophy modeling in vivo (Table 4). 
 Microcarriers carry some additional disadvantages regarding the culture method and 
morphology. The monolayer of tissue that forms over the bead surfaces does not replicate three-
dimensional mature tissue in vivo. Compared to astronauts that begin with differentiated muscle 
tissue, microcarriers are first seeded with undifferentiated myoblasts which form multi-nucleated 
myotubes during culture. Despite this difference, the model remains clinically relevant as fusion 
and differentiation of muscle cells are important parts of myogenesis in adults[126]. Another 
disadvantage of microcarriers is the large variations in cluster diameter relative to alginate beads 
(Table 2). As settling rate within the RCCS varies with substrate diameter, a portion of the 
microcarrier clusters will not be maintained at the optimal settling rate to simulate microgravity. 
Additionally, bead cluster size increases over time, requiring daily monitoring and RPM 
adjustment. 
 While alginate did not support the desired changes in atrophy marker expression, it offers 
some beneficial properties compared to microcarriers. Alginate encapsulation of differentiated 
cells in a three-dimensional conformation improves morphological biosimilarity to mature tissue. 




(Figure 23C). Encapsulation also protects cells from exposure to mechanical stress within the 
RCCS. Fluid flow in the RCCS is designed to provide a low shear environment[54]. Still, cells 
experience mechanical stress from collisions of suspended substrates due to the rotation of the 
system. While cells encapsulated in alginate are protected from direct contact, the exposed nature 
of cells cultured on microcarriers means that collisions between beads will result in a direct 
impact to the cells. Furthermore, alginate beads have a more consistent size than microcarrier 
bead clusters and did not display the same variations in settling rate or require changes in the 
RCCS’ RPM (Table 2). 
The downsides of alginate, in addition to the lack of significant changes in atrophy 
marker expression, stem from their density, size, and opacity. While the solid structure of 
alginate protects cells from mechanical stress, it also limits the spreading of encapsulated cells, 
preventing formation of intercellular junctions necessary for myoblast fusion (Figure 23A). In 
contrast to the small and easy to handle microcarriers, alginate beads, with a diameter of 
3252±103 µm, were too large to be aspirated into a pipette. Smaller alginate beads can be formed 
by using a higher gauge needle, but narrower needles were clogged by the large sheets of 
differentiated muscle tissue seen in Figure 23B. The large bead size also complicated imaging 
due to the opacity of alginate, which scattered too much light to allow fluorescent imaging of the 
interior without fixation and sectioning. While these issues are addressable with process 
modifications, the most significant issue is that nutrient and waste diffusion rates are dependent 
on depth, such that beads with tissues closer to the surface may behave differently than those 
with tissues encapsulated in the center. As the position of tissues within the bead is random, we 
attribute some of the variability in encapsulated differentiated samples to uneven distribution of 




 Overall, culturing with microcarrier beads provides a better platform than alginate 
encapsulation for modeling muscular atrophy in C2C12 cells, though this model does not 
completely mimic the mRNA changes seen in vivo. Cultures on microcarrier beads resulted in 
irregular clusters covered with a monolayer of cells and sporadic myotubes (Figure 22) and 
appropriate atrophy marker expression to mimic in vivo studies only with regard to MuRF1, 
Caspase 3, and Foxo3, albeit with lower—but still significant—fold changes for MuRF1 and 
Foxo3 (Table 4). On the other hand, cultures with encapsulated cells resulted in static, regularly 
dispersed undifferentiated cells (Figure 23A) or unevenly dispersed sheets of differentiated tissue 
(Figure 23B) without consistent increases in expression of the selected atrophy markers. 
Therefore, we conclude that an in vitro model of microgravity-induced muscle atrophy using 
polystyrene microcarrier beads is superior to alginate encapsulation for cultured C2C12 cells, but 
not sufficient to mimic all of the select atrophy markers as in animal studies. Of the culture 
methods evaluated, the most significant and consistent increase in the selected atrophy markers, 
relative to GAPDH (Figure 25) was achieved with microcarriers cultured in static ULA flasks for 
12 days, then moved to the RCCS for the final 3 days. 
 Our verification that the RCCS can produce increases in atrophy-specific mRNAs in 
cultured muscle cells is an important step towards completing a comprehensive ground-based in 
vitro model for spaceflight atrophy. Due to the lower number of atrophy markers upregulated 
and the lower fold changes in expression, relative to animal models, we believe the standard 
commercially available RCCS is not sufficient for use in vitro atrophy modeling and it does not 
match results in vivo. Nevertheless, our results in vitro are highly significant for MuRF1 
(p<0.01), Foxo3 (p<0.01), and Caspase 3 (p<0.001), indicating that with further development, 




pathways and first-step design and selection of novel therapeutics necessary to ensure astronaut 





 Overall, culturing with microcarrier beads provides a better platform for modeling 
microgravity-induced muscular atrophy with C2C12 cells than alginate encapsulation. Cultures 
on microcarrier beads resulted in irregular clusters covered with a monolayer of cells and 
sporadic myotubes, but allowed for ease of handling and, most importantly, resulted in 
appropriate atrophy marker expression to mimic hind limb unloading studies with regard to 
several key markers. On the other hand, cultures with encapsulated cells resulted in static, 
regularly dispersed undifferentiated cells or unevenly dispersed sheets of differentiated tissue 
without consistent increases in expression of the selected atrophy markers. Therefore, we 
conclude that an in vitro model of microgravity-induced muscle atrophy using polystyrene 
microcarrier beads is superior to alginate encapsulation for cultured C2C12 cells. To induce the 
most significant and consistent increase in these same atrophy markers, relative to GAPDH, a 
normal gravity control with microcarriers in static ULA flasks should be cultured for 15 days and 
compared with microcarriers cultured for 12 days in the same flasks, then moved to the RCCS 
for the final 3 days. 
Due to variations in microcarrier bead cluster size, not all of the cells are maintained at 
the optimal settling rate to simulate microgravity. Despite the presence of such variations, 




MuRF1, MAFbx, and caspase-3 than normal gravity controls. Alginate beads, having a more 
consistent size, did not display the same variations in settling rate. However, neither 
undifferentiated nor differentiated cells expressed significant increases in all three mRNA 
markers. 
 The verification that the RCCS can partially model atrophic conditions in cultured muscle 
cells is an important step towards completing a comprehensive ground-based in vitro model for 
spaceflight atrophy. Our ongoing work focuses on evaluating the effectiveness of antioxidants in 
attenuating the increase in MuRF1, MAFbx, and Caspase 3 seen with C2C12 cells cultured in 
simulated microgravity on microcarriers. We are also investigating adding radiation to more 
accurately simulate spaceflight conditions. The simulated microgravity model described herein 
produces increases in the same mRNA markers of muscular atrophy as in vivo hind limb 
unloading models, presenting a promising system for investigation of atrophy pathways and first-
step design and selection of novel therapeutics necessary to ensure astronaut health and fitness 
during long-term spaceflight. Further development of the model with additional cell types, 
optimized encapsulation and additional microcarrier materials could improve biosimilarity. 
Combined with PCR arrays targeting a large number of genes, the model presented herein can 
help elucidate the mechanisms of action for atrophy countermeasures, providing a foundation for 
design and selection of novel therapeutics. 
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RCCS OPERATION WITH MICROCARRIERS AND ALGINATE 
 
 Lab protocols for operation of the Synthecon RCCS-4H, use of microcarrier beads, and 
alginate encapsulation are demonstrated in the video linked below. Demonstration and filming 
by Charles P. Harding, editing by Matt Clegg. 
https://usu.box.com/s/pdtf48bzqcyank1mskkg2j1dcefeu7y2 
